Benjamin Cossins
About Benjamin Cossins
Benjamin Cossins serves as the Head of Design Development (Interim) at Exscientia in Oxford, England, where he has worked since 2024. He has extensive experience in molecular dynamics and drug discovery, having held various roles in academia and industry over the past two decades.
Current Role at Exscientia
Benjamin Cossins serves as the Head of Design Development (Interim) at Exscientia, a position he has held since 2024. He is based in Oxford, England, United Kingdom. In addition to this interim role, he has been the Director of Molecular Dynamics at Exscientia since 2021. His work focuses on integrating computational methods into the drug discovery process, enhancing the understanding of molecular interactions.
Previous Experience
Before joining Exscientia, Benjamin Cossins worked at UCB as a Principal Scientist from 2011 to 2021. His earlier experience includes a post-doctoral position at the Barcelona Supercomputing Center from 2007 to 2010. He also completed his PhD at the University of Southampton from 2003 to 2007, which provided a strong foundation for his subsequent research career.
Educational Background
Benjamin Cossins completed his Bachelor of Science (BS) in Biochemistry and Genetics at The University of Sheffield from 1996 to 1999. He then pursued a Master of Research (MRes) in Bioinformatics at Birkbeck, University of London from 2002 to 2003. His academic journey culminated in a PhD from the University of Southampton, where he studied from 2003 to 2007.
Research Interests
Cossins has a keen interest in understanding cellular functions at an atomistic level, utilizing computational and statistical physics. His research focuses on predicting molecular recognition, conformational changes, and allostery. He aims to develop new methodologies that are integral to the drug discovery process, contributing to advancements in the field.
Future Aspirations
Benjamin Cossins aspires to take on a senior role in strategic decision-making regarding research directions in the future. His experience and expertise position him well to influence research initiatives and methodologies within the pharmaceutical industry.